Skip to main content
Sandoz reports clinical trial data on 2 biosimilars
11/14/2017

Novartis unit Sandoz reported that its biosimilar version of adalimumab had safety and efficacy profiles similar to those of AbbVie's Humira, and its rituximab matched the safety and efficacy of Roche and Biogen's Rituxan.

Full Story: